Literature DB >> 16189083

Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility.

Hui-Ling Yen1, Louise M Herlocher, Erich Hoffmann, Mikhail N Matrosovich, Arnold S Monto, Robert G Webster, Elena A Govorkova.   

Abstract

Mutations of the conserved residues of influenza virus neuraminidase (NA) that are associated with NA inhibitor (NAI) resistance decrease the sialidase activity and/or stability of the NA, thus compromising viral fitness. In fact, clinically derived NAI-resistant variants with different NA mutations have shown different transmissibilities in ferrets (M. L. Herlocher, R. Truscon, S. Elias, H. Yen, N. A. Roberts, S. E. Ohmit, and A. S. Monto, J. Infect. Dis. 190:1627-1630, 2004). Molecular characterization of mutant viruses that have a homogeneous genetic background is required to determine the effect of single mutations at conserved NA residues. We generated recombinant viruses containing either the wild-type NA (RG WT virus) or a single amino acid change at NA residue 119 (RG E119V-NA virus) or 292 (RG R292K-NA virus) in the A/Wuhan/359/95 (H3N2) influenza virus background by reverse genetics. Both mutants showed decreased sensitivity to oseltamivir carboxylate, and the RG R292K-NA virus showed cross-resistance to zanamivir. We also observed differences between the two mutants in NA enzymatic activity and thermostability. The R292K mutation caused greater reduction of sialidase activity and thermostability than the E119V mutation. The NA defect caused by the R292K mutation was associated with compromised growth and transmissibility, whereas the growth and transmissibility of the RG E119V-NA virus were comparable to those of RG WT virus. Our results suggest that NAI-resistant influenza virus variants may differ substantially in fitness and transmissibility, depending on different levels of NA functional loss.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16189083      PMCID: PMC1251536          DOI: 10.1128/AAC.49.10.4075-4084.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

Review 1.  Resistance of influenza viruses to neuraminidase inhibitors--a review.

Authors:  J L McKimm-Breschkin
Journal:  Antiviral Res       Date:  2000-07       Impact factor: 5.970

Review 2.  Functional balance between haemagglutinin and neuraminidase in influenza virus infections.

Authors:  Ralf Wagner; Mikhail Matrosovich; Hans-Dieter Klenk
Journal:  Rev Med Virol       Date:  2002 May-Jun       Impact factor: 6.989

Review 3.  Position statement: global neuraminidase inhibitor susceptibility network.

Authors:  M Zambon; F G Hayden
Journal:  Antiviral Res       Date:  2001-03       Impact factor: 5.970

Review 4.  Neuraminidase inhibitors for the treatment and prevention of influenza.

Authors:  Jennifer L McKimm-Breschkin
Journal:  Expert Opin Pharmacother       Date:  2002-02       Impact factor: 3.889

5.  Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay.

Authors:  Larisa V Gubareva; Robert G Webster; Frederick G Hayden
Journal:  Antiviral Res       Date:  2002-01       Impact factor: 5.970

6.  Universal primer set for the full-length amplification of all influenza A viruses.

Authors:  E Hoffmann; J Stech; Y Guan; R G Webster; D R Perez
Journal:  Arch Virol       Date:  2001-12       Impact factor: 2.574

7.  Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus.

Authors:  L J Mitnaul; M N Matrosovich; M R Castrucci; A B Tuzikov; N V Bovin; D Kobasa; Y Kawaoka
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

8.  Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.

Authors:  L V Gubareva; R G Webster; F G Hayden
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

9.  Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors.

Authors:  Mikhail Matrosovich; Tatyana Matrosovich; Jackie Carr; Noel A Roberts; Hans-Dieter Klenk
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

Review 10.  Influenza virus neuraminidase inhibitors.

Authors:  L V Gubareva; L Kaiser; F G Hayden
Journal:  Lancet       Date:  2000-03-04       Impact factor: 79.321

View more
  105 in total

1.  The 2008-2009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: Implications for the prevalence of oseltamivir resistant variant viruses.

Authors:  Wai Lan Wu; Siu-Ying Lau; Yixin Chen; Genyan Wang; Bobo Wing-Yee Mok; Xi Wen; Pui Wang; Wenjun Song; Tianwei Lin; Kwok-Hung Chan; Kwok-Yung Yuen; Honglin Chen
Journal:  Antiviral Res       Date:  2011-11-25       Impact factor: 5.970

2.  Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses.

Authors:  Hui-Ling Yen; Erich Hoffmann; Garry Taylor; Christoph Scholtissek; Arnold S Monto; Robert G Webster; Elena A Govorkova
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir.

Authors:  M A Rameix-Welti; F Agou; P Buchy; S Mardy; J T Aubin; M Véron; S van der Werf; N Naffakh
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

4.  The effect of population structure on the emergence of drug resistance during influenza pandemics.

Authors:  Florence Débarre; Sebastian Bonhoeffer; Roland R Regoes
Journal:  J R Soc Interface       Date:  2007-10-22       Impact factor: 4.118

5.  Emergence of drug resistance: implications for antiviral control of pandemic influenza.

Authors:  Murray E Alexander; Christopher S Bowman; Zhilan Feng; Michael Gardam; Seyed M Moghadas; Gergely Röst; Jianhong Wu; Ping Yan
Journal:  Proc Biol Sci       Date:  2007-07-22       Impact factor: 5.349

6.  Management of drug resistance in the population: influenza as a case study.

Authors:  Seyed M Moghadas
Journal:  Proc Biol Sci       Date:  2008-05-22       Impact factor: 5.349

7.  Analysis of oseltamivir resistance substitutions in influenza virus glycoprotein neuraminidase using a lentivirus-based surrogate assay system.

Authors:  Jennifer Tisoncik-Go; Katie S Cordero; Lijun Rong
Journal:  Virol Sin       Date:  2013-02-06       Impact factor: 4.327

8.  Antiviral resistance and the control of pandemic influenza: the roles of stochasticity, evolution and model details.

Authors:  Andreas Handel; Ira M Longini; Rustom Antia
Journal:  J Theor Biol       Date:  2008-10-08       Impact factor: 2.691

9.  Bifunctional polymeric inhibitors of human influenza A viruses.

Authors:  Jayanta Haldar; Luis Alvarez de Cienfuegos; Terrence M Tumpey; Larisa V Gubareva; Jianzhu Chen; Alexander M Klibanov
Journal:  Pharm Res       Date:  2009-12-15       Impact factor: 4.200

10.  Effect of oseltamivir carboxylate consumption on emergence of drug-resistant H5N2 avian influenza virus in Mallard ducks.

Authors:  Jenna E Achenbach; Richard A Bowen
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.